Glimpses
that are ideal for the needs of today’s
sports sunglass wearers.
The combined offering of Tifosi frames
and Hoya lenses will allow eyecare
professionals to exploit a value price
point while procuring new patients
and improved margins. The partner-
ship brings a distinct advantage to
Independent Eyecare by providing
a dedicated laboratory that excels
in producing lenses for Tifosi frame
styles to help provide the ECP with
a clean and simple offering that
provides outstanding quality, great
delivery times and superior margins.
J&J Vision acquires
TearScience
Hoya partners with
Tifosi Optics
Hoya Vision Care has announced that
it will be partnering with Tifosi Optics
to expand prescription sunglass
offerings for both eye care professionals
and consumers.
This partnership is a strategic one
for both companies and seeks to offer
Independent Eyecare Professionals
with new and exciting product offerings
in the Rx sunglass market.
HOYA and Tifosi understand that eye
care professionals prefer to partner
with independently owned brands that
are not competing with eye care
professionals directly for consumers.
Tifosi Optics was founded in 2003 and
remains independently owned by
founders Joe and Elizabeth Earley, who
have been offering sport sunglasses
46 Optical Prism | October 2017
Johnson & Johnson Vision has com-
pleted its acquisition of TearScience,
Inc., a medical device manufacturer
dedicated to evaluating meibomian
gland health and treating Meibomian
Gland Dysfunction (MGD), the leading
cause of Dry Eye Disease (Dry Eye)
i. The acquisition is another step in
Johnson & Johnson Vision’s strategy
to become a broad-based, global leader
in eye health and further expands the
company’s leading eye health portfolio.
“Dry Eye is too often the culprit of why
patients drop out of contact lenses or
why they may have a less than optimal
outcome from their cataract surgery,”
said Ashley McEvoy, Company Group
Chairman, responsible for the John-
son & Johnson Vision Companies.
“The medical device technologies from
TearScience will allow us to address
the main underlying cause of Dry Eye,
giving us a mechanical solution to a
mechanical problem.”
Dry Eye impacts an estimated 340
million people globally, and MGD, a
chronic, progressive condition that can
range from mild to severe pain, is the
leading cause. Patients with MGD may
present in an optometrist’s office or at
an ophthalmology appointment, so
the disease is treated across the eye
care community. TearScience technolo-
gies allow physicians to evaluate mei-
bomian gland health and treat MGD
with a 12-minute in-office treatment.
Johnson & Johnson Vision acquired
TearScience, Inc., through its surgical
vision operating company, Abbott Med-
ical Optics Inc. Sales will be reported in
the Medical Devices segment, under
Vision Care. Financial terms of the
transaction have not been disclosed.